Operating cash flow has tracked 66% to 95% of net loss, with free cash flow of -$15.4M in 2026Q3 and no dividends, buybacks, or acquisitions, meaning all operating burn must be funded externally.
Design Therapeutics, Inc. (DSGN) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | -59.3M | -54.36M | -43.1M | -58.56M | -51.32M | -29.38M | -8.67M | -139K |
| Operating CF Margin % | - | - | - | - | - | - | - | -16666.67% |
| Operating CF Growth % | -64.5% | -26.11% | 26.39% | -14.11% | -74.68% | -238.87% | -6136.69% | - |
| Net Income | -74.09M | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M | -2.05M |
| Depreciation & Amortization | 457K | 622K | 596K | 537K | 406K | 129K | 5K | 1.91M |
| Stock-Based Compensation | 15.28M | 14.55M | 13.07M | 13.09M | 10.93M | 4.69M | 450K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -376K | -2.85M | -6.19M | -6.05M | -1.33M | -58K | -33K | -1.81M |
| Working Capital Changes | -571K | 3.11M | -993K | 728K | 1.99M | 1.4M | -811K | 1.81M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.73M | 4.49M | -1.22M | -1.25M | 5.38M | 2.41M | -413K | 0 |
| Cash from Investing | -3.93M | 22.91M | 43.95M | 52.54M | -220.99M | -53.64M | -33.56M | 0 |
| Capital Expenditures | -70K | -193K | -340K | -256K | -918K | -1.54M | -76K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 39K | 52.11K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -52.11K | 0 | 0 |
| Cash from Financing | 63.39M | 25.74M | 513K | 724K | 235K | 379.21M | 44.53M | 196K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -200K | 196K |
| Equity Issued (Net) | 63.39M | 25.74M | 513K | 724K | 662K | 378.98M | 44.73M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | -427K | 228K | 1K | 0 |
| Net Change in Cash | 164K | -5.71M | 1.36M | -5.3M | -272.07M | 296.19M | 2.3M | 57K |
| Free Cash Flow | -59.37M | -54.55M | -43.45M | -58.82M | -52.23M | -30.91M | -8.74M | -139K |
| FCF Margin % | - | - | - | - | - | - | - | -16666.67% |
| FCF Growth % | -13.28% | -25.56% | 26.13% | -12.6% | -68.96% | -253.52% | -6191.37% | - |
| FCF per Share | -0.94 | -0.95 | -0.77 | -1.05 | -0.94 | -0.67 | -0.32 | -0.01 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.78x | 0.87x | 0.88x | 0.81x | 0.83x | 1.05x | 0.07x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 24K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying DSGN stock.
Design Therapeutics, Inc. (DSGN) generated $-54.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Design Therapeutics, Inc. (DSGN) reported negative free cash flow of $54.6M in 2025, indicating capital requirements exceeded cash from operations.
Design Therapeutics, Inc. (DSGN) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Limited cash runway
Metrics are mathematically derived from official filings.
Operating Cash Burn Tracks Losses Closely
According to the reported cash flow statement, DSGN's operating cash flow has run between roughly 66% and 95% of reported net loss over the ten quarters shown, indicating that the bulk of the accounting loss is a real cash outflow rather than a non-cash charge.
The operating cash flow to net income ratio ranges from 0.66 in 2025Q3 to 0.95 in 2024Q2 and 2025Q1, meaning net losses are not being materially cushioned by accruals. Stock-based compensation of $3.1M to $4.1M per quarter explains only part of the gap, so the remaining cash burn appears driven by clinical and R&D spending. This suggests the earnings quality concern is less about accrual manipulation and more about the pace at which cash is consumed by development activity.
Free Cash Flow Deficit Widened Into 2026
As reported in the cash flow statements, DSGN's free cash flow deteriorated from roughly -$9.5M in 2024Q3 to -$15.4M in 2026Q3, with negligible capital expenditure contributing to the trend.
Because capital expenditure is near zero in nearly every quarter, free cash flow is effectively equal to operating cash flow, and the deficit is entirely an operating phenomenon. The approximately 60% increase in quarterly burn over two years appears consistent with an expanding clinical program rather than deteriorating unit economics. Investors should monitor whether the burn rate is stabilizing or continuing to accelerate as later-stage trials scale.
Working Capital Swings Mask Underlying Burn
Based on DSGN's reported figures, working capital changes have alternated between large outflows of -$2.8M in 2026Q1 and inflows of up to $2.9M in 2025Q3, creating quarter-to-quarter volatility that obscures the underlying cash trend.
These swings appear to reflect timing of payables and prepaid clinical commitments rather than changes in operating efficiency, given the absence of revenue or inventory. The 2026Q1 outflow coincided with the sharpest quarterly operating burn in the period, suggesting that some expense recognition may have been pulled forward or settled in that quarter. Analysts should look at trailing averages rather than individual quarters to isolate the true run-rate.
No Shareholder Returns Amid Equity Dependence
DSGN reported zero dividends, buybacks, or acquisition spending across all ten quarters, so every dollar of cash consumed by operations must be funded externally.
The absence of capital returns is expected for a pre-revenue biotech, but it means the company's entire capital structure exists to fund clinical development. The reported 0.01 debt-to-equity ratio alongside negative ROE of -30.7% suggests reliance on equity issuance rather than leverage. Based on reported figures, the financing requirement warrants further investigation as the quarterly operating burn of roughly $15M to $16M appears to outpace the last disclosed cash balance of $16.9M.
Cash Flow Data Gaps Limit Runway Assessment
The cash flow data provided does not include a current cash balance, so runway estimates rely on a previously reported $16.9M figure against quarterly burn near $15.4M.
If the most recent cash position is close to the prior disclosure, the implied runway would be roughly one quarter at current burn rates, a conclusion that appears to warrant urgent review of the balance sheet. Alternatively, undisclosed financing transactions after the last reported balance may have extended liquidity, and that possibility cannot be ruled out from the supplied data. Investors should treat the absence of a current cash figure as a material gap rather than assume either outcome.